Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  11:36 2022-12-09 am EST
1.580 EUR    0.00%
12/08Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
12/08Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Country
CI
11/23Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board

08/25/2022 | 04:31am EST

Biofrontera AG announces the election of Prof. Dr. Karin Lergenmüller to the Supervisory Board at the Annual General Meeting on August 23, 2022. The attending shareholders represented approximately 46% of the registered share capital. Following Prof. Dr. Ruhwendel's resignation from the Supervisory Board in February 2022, a sixth position on the Supervisory Board of Biofrontera AG was temporarily vacant.

The management submitted a proposed resolution to Annual General Meeting to downsize the Supervisory Board to five members, which was, however, rejected by the shareholders. The appointment of Prof. Lergenmüller to the Supervisory Board of Biofrontera AG, as proposed by Deutsche Balaton AG by way of a supplementary motion, was approved by a majority of 73.6% of the share capital permitted to be represented at the Annual General Meeting. Prof. Lergenmüller worked for Deutsche Bank AG after holding positions in the management consulting industry, including at Andersen Consulting and Gemini Consulting.

From 1996 to 1998 she was a member of the management of Joas & Comp., Bad Homburg. Since 1999, Prof. Dr. Karin Lergenmüller has been Professor of Marketing and General Business Administration at the Rhine-Main University of Applied Sciences, Wiesbaden. Since 2000 Prof. Dr. Karin Lergenmüller is Global Equity Investor, specialized in Digital World, Technology companies, NFT's and Crypto.

Furthermore, Prof. Lergenmüller holds various supervisory board mandates in companies of the Deutsche Balaton Group.


© S&P Capital IQ 2022
All news about BIOFRONTERA AG
12/08Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
12/08Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Coun..
CI
11/23Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022
CI
11/23Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/14Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
10/31Biofrontera Says It Has Agreed to Buy Biofrontera AG Options
MT
10/28BIOFRONTERA AG : RIGHTS ISSUE: 1 new share @ 1 EUR for 8 existing shares
FA
10/24Biofrontera Appoints Fred Leffler as CFO
MT
10/14Biofrontera Adopts Shareholder Rights Plan
MT
10/05Biofrontera Reports Preliminary Q3 Product Revenue -- Stock Down 7% After-Hours
MT
More news
Financials
Sales 2022 26,2 M 27,6 M 27,6 M
Net income 2022 -38,1 M -40,2 M -40,2 M
Net Debt 2022 - - -
P/E ratio 2022 -2,63x
Yield 2022 -
Capitalization 89,6 M 94,4 M 94,4 M
Capi. / Sales 2022 3,42x
Capi. / Sales 2023 2,94x
Nbr of Employees 102
Free-Float 49,7%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,58 €
Average target price 2,80 €
Spread / Average Target 77,2%
EPS Revisions
Managers and Directors
Maria del Pilar de la Huerta Martinez Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG11.74%95
CSL LIMITED2.33%96 965
SAMSUNG BIOLOGICS CO.,LTD.-8.42%44 692
BIOGEN INC.20.50%41 631
WUXI BIOLOGICS (CAYMAN) INC.-39.98%30 132
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.36%19 486